Literature DB >> 9686892

Automated determination of clomipramine and its major metabolites in human and rat serum by high-performance liquid chromatography with on-line column-switching.

H Weigmann1, S Härtter, C Hiemke.   

Abstract

A fully automated method including column-switching and isocratic high-performance liquid chromatography (HPLC) was developed for simultaneous determination of the tricyclic antidepressant clomipramine and its metabolites demethylclomipramine, 2-, 8-, and 10-hydroxyclomipramine, 2-, and 8-hydroxydemethylclomipramine and didemethylclomipramine in serum. After serum injection into the HPLC system and on-line sample clean-up on a clean-up column (Hypersil CN; 10 x 4.6 mm) by an eluent consisting of 35% acetonitrile and 65% deionized water, the chromatographic separation was performed on an analytical column (LiChrospher CN; 250 x 4.6 mm I.D.) by an eluent consisting of 38% acetonitrile and 62% aqueous sodium perchlorate (0.02 M, pH 2.5). The UV detector was set at 260 nm. The limit of quantification was about 15 ng/ml for all analytes. The coefficients of variation ranged between 3 and 12% with recovery rates between 64 and 110%. Linear regression analyses revealed coefficients of correlation between 0.98 and 0.99. The method could be applied to therapeutic drug monitoring as well as metabolism studies in man and rat.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9686892     DOI: 10.1016/s0378-4347(98)00129-7

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  2 in total

1.  Region specific distribution of levomepromazine in the human brain.

Authors:  J Kornhuber; H Weigmann; J Röhrich; J Wiltfang; S Bleich; I Meineke; R Zöchling; S Härtter; P Riederer; C Hiemke
Journal:  J Neural Transm (Vienna)       Date:  2005-07-06       Impact factor: 3.575

Review 2.  Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?

Authors:  Christoph Hiemke
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03       Impact factor: 5.270

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.